(51) International Patent Classification⁷: **C12N**

(21) International Application Number: PCT/US02/29964

(22) International Filing Date:
19 September 2002 (19.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/323,739   19 September 2001 (19.09.2001)   US
Not furnished   13 September 2002 (13.09.2002)   US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US   Not furnished (CIP)
Filed on   Not furnished

(71) Applicant *(for all designated States except US)*: **HYSEQ, INC.** [US/US]; 670 Almanor Avenue, Sunnyvale, CA 94085 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **TANG, Y., Tom** [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **ASUNDI, Vinod** [US/US]; 709 Foster City Boulevard, Foster City, CA 94404 (US). **GOODRICH, Ryle, W.** [US/US]; 3461 Saint Susan Place, Los Angeles, CA 90066 (US). **REN, Feiyan** [US/US]; 7703 Oak Meadow Court, Cupertino, CA 95014 (US). **ZHANG, Jie** [CN/US]; 4930 Poplar Terrace, Campbell, CA 95008 (US). **ZHAO, Qing, A.** [CN/US]; 1556 Kooser Rd, San Jose, CA 95118 (US). **WANG, Jian-Rui** [CN/US]; 744 Stendhal Lane, Cupertino, CA 95014 (US). **GHOSH, Malabika** [IN/US]; 620 Iris Avenue, Apt. 133, Sunnyvale, CA 94086 (US). **XUE, Aidong, J.** [US/US]; 1621 S. Mary Avenue, Sunnyvale, CA 94087 (US). **WEHRMAN, Tom**

[US/US]; CCSR Mol Pharm 3210, 269 W. Campus Dr, Stanford, CA 94305 (US). **WENG, Gezhi** [US/US]; 415 Moraga Avenue, Piedmont, CA 94611 (US). **ZHOU, Ping** [US/US]; 7595 Newcastle Drive, Cupertino, CA 95014 (US). **DRMANAC, Radoje, T.** [US/US]; 850 East Greenwich Place, Palo Alto, CA 94303 (US). **WANG, Dunrui** [CN/US]; 12252 Pepper Tree Lane, Poway, CA 92064 (US). **HALEY-VICENTE, Dana** [US/US]; 1305 Eagle Glen, Escondido, CA 92029 (US).

(74) Agents: **RIN-LAURES, Li-Hsien** et al.; Hyseq, Inc., 670 Almanor Avenue, Sunnyvale, CA 94085 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES

(57) **Abstract:** The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

Left column

RESULT 2

```
ID   AD121099 standard; protein; 271 AA.
XX
AC   AD121099;
XX
DT   15-APR-2004  (first entry)
XX
DE   Novel human protein #74.
XX
```

```
forensic; nutritional source; damaged tissue; diseased tissue;
myeloid cell disorder; lymphoid cell disorder;
one cartilage tissue growth; tendon tissue growth;
'ament tissue growth; nerve tissue growth; regeneration; wound healing;
'ue repair; tissue replacement; burn; incision; ulcer; cancer; human.
```

```
XX
PF  23-JUL-2001; 2001WO-US023124.
XX
PR  24-JUL-2000; 2000US-0220116P.
PR  27-JUL-2000; 2000US-0221143P.
XX
PA  (HUMA-) HUMAN GENOME SCI INC.
XX
PI  Zeng Z, Ruben SM, Rosen CA;
XX
DR  WPI; 2002-171948/22.
DR  N-PSDB; AAD33366.
XX
PT  Two novel proteins, TR21 and TR22, which are members of the tumor
PT  necrosis factor receptor, useful for the diagnosis and treatment of
PT  immune disorders, cancer, cardiovascular disorders.
XX
PT  Claim 11; Fig 1; 248pp; English.
XX
CC  The present invention relates to novel human tumour necrosis factor (TNF)
CC  receptors, TR21 and TR22 and polynucleotides encoding them. Sequences of
CC  the invention are useful in the diagnosis, treatment and prevention of
CC  cancers (e.g. cancers of the adrenal gland, bone, urogenital or bone
CC  marrow, in particular breast and ovarian cancer), immune disorders (e.g.,
CC  autoimmune haemolytic anaemia, rheumatoid arthritis, allergies, Addison's
CC  disease, ulcerative colitis), cardiovascular disorders (e.g., myocardial
CC  ischaemia), wound healing, neurological diseases (e.g., cerebral anoxia,
CC  epilepsy) and infectious diseases such as viral, bacterial, fungal and
CC  parasitic infections. They are also useful in gene therapy. The present
CC  sequence is human TR21 protein
XX
SQ  Sequence 271 AA;
```

```
Query Match             100.0%;  Score 1426; DB 5;  Length 271;
Best Local Similarity   100.0%;  Pred. No. 1.1e-120;
Matches  271;  Conservative   0;  Mismatches  0;  Indels   0;  Gaps   0;
```

```
Qy     1  MAPRALPGSAVLAAAVPVGGAVSSPLVAPDNGSSRTLHSRTETTPSPSNDTGNGHPEYIA 60
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     1  MAPRALPGSAVLAAAVPVGGAVSSPLVAPDNGSSRTLHSRTETTPSPSNDTGNGHPEYIA 60

Qy    61  YALVPVFFIMGLFGVLICHLLKKKGYRCTTEAEQDIEEEKVEKIELNDSVNENSDTVGQI 120
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    61  YALVPVFFIMGLFGVLICHLLKKKGYRCTTEAEQDIEEEKVEKIELNDSVNENSDTVGQI 120

Qy   121  VHYIMKNEANADVLKAMVADNSLYDPESPVTPSTPGSPPVSPGPLSPGGTPGKHVCGHHL 180
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   121  VHYIMKNEANADVLKAMVADNSLYDPESPVTPSTPGSPPVSPGPLSPGGTPGKHVCGHHL 180

Qy   181  HTVGGVVERDVCHRCRHKRWHFIKPTNKSRESRPRRQGEVTVLSVGRFRVTKVEHKSNQK 240
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   181  HTVGGVVERDVCHRCRHKRWHFIKPTNKSRESRPRRQGEVTVLSVGRFRVTKVEHKSNQK 240

Qy   241  ERRSLMSVSGAETVNGEVPATPVKRERSGTE 271
          |||||||||||||||||||||||||||||||
Db   241  ERRSLMSVSGAETVNGEVPATPVKRERSGTE 271
```

Right column

```
XX
PA  (HYSE-) HYSEQ INC.
XX
PR  19-SEP-2002; 2002WO-US029964.
PR  19-SEP-2001; 2001US-0323739P.
PR  13-SEP-2002; 2002US-00323739.
XX
PD  27-MAR-2003.
XX
PN  WO2003025148-A2.
XX
OS  Homo sapiens.
XX
PI  Tang YT,  Asundi V,  Goodrich RW,  Ren F,  Zhang J,  Zhao QA,  Wang J;
PI  Ghosh M,  Xue AJ,  Wehrman T,  Weng G,  Zhou P,  Drmanac RT,  Wang D;
PI  Haley-Vicente D;
XX
DR  WPI; 2003-354603/33.
DR  N-PSDB; AD121815.
XX
PT  New polynucleotides and secreted proteins, useful for treating myeloid or
PT  lymphoid cell disorders, in bone cartilage, tendon, ligament and nerve
PT  tissue growth or regeneration, in wound healing, and in tissue repair and
PT  replacement.
XX
PT  Claim 20; SEQ ID NO 350; 156pp; English.
XX
CC  The invention relates to an isolated polynucleotide encoding a
CC  polypeptide with biological activity. The polynucleotides and
CC  polypeptides are useful in diagnostics, forensics, gene mapping,
CC  identification of mutations responsible for genetic disorders and other
CC  traits, to assess biodiversity, as nutritional sources or supplements.
CC  The polynucleotides may also be used as molecular weight markers,
CC  chromosome markers or map related gene positions, or as an antigen to
CC  raise anti-DNA antibodies or elicit immune response. The polypeptides are
CC  useful for raising antibodies, as markers for tissues in which the
CC  corresponding polypeptide is expressed, for re-engineering damaged or
CC  diseased tissues, for treating myeloid or lymphoid cell disorders, in
CC  bone cartilage, tendon, ligament and/or nerve tissue growth or
CC  regeneration, in wound healing, in tissue repair and replacement, in
CC  healing of burns, incisions and ulcers, and in treating cancer. The
CC  present sequence represents the amino acid sequence of a novel human
CC  protein.
XX
SQ  Sequence 271 AA;
```

```
Query Match             100.0%;  Score 1426; DB 7;  Length 271;
Best Local Similarity   100.0%;  Pred. No. 1.1e-120;
Matches  271;  Conservative   0;  Mismatches  0;  Indels   0;  Gaps   0;
```

```
Qy     1  MAPRALPGSAVLAAAVPVGGAVSSPLVAPDNGSSRTLHSRTETTPSPSNDTGNGHPEYIA 60
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     1  MAPRALPGSAVLAAAVPVGGAVSSPLVAPDNGSSRTLHSRTETTPSPSNDTGNGHPEYIA 60

Qy    61  YALVPVFFIMGLFGVLICHLLKKKGYRCTTEAEQDIEEEKVEKIELNDSVNENSDTVGQI 120
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    61  YALVPVFFIMGLFGVLICHLLKKKGYRCTTEAEQDIEEEKVEKIELNDSVNENSDTVGQI 120

Qy   121  VHYIMKNEANADVLKAMVADNSLYDPESPVTPSTPGSPPVSPGPLSPGGTPGKHVCGHHL 180
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   121  VHYIMKNEANADVLKAMVADNSLYDPESPVTPSTPGSPPVSPGPLSPGGTPGKHVCGHHL 180

Qy   181  HTVGGVVERDVCHRCRHKRWHFIKPTNKSRESRPRRQGEVTVLSVGRFRVTKVEHKSNQK 240
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db   181  HTVGGVVERDVCHRCRHKRWHFIKPTNKSRESRPRRQGEVTVLSVGRFRVTKVEHKSNQK 240

Qy   241  ERRSLMSVSGAETVNGEVPATPVKRERSGTE 271
          |||||||||||||||||||||||||||||||
Db   241  ERRSLMSVSGAETVNGEVPATPVKRERSGTE 271
```

RESULT 3